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Abstract
Objectives: Jaundice impairs cellular immunity, an important defence against the dissemination of
cancer. Jaundice is a common mode of presentation in pancreatic head adenocarcinoma. The purpose
of this study was to determine whether there is an association between preoperative jaundice and survival
in patients who have undergone resection of such tumours.
Methods: Thirty possible survival risk factors were evaluated in a database of over 400 resected
patients. Univariate analysis was used to determine odds ratio for death. All factors for which a P-value
of <0.30 was obtained were entered into a multivariate analysis using the Cox model with backward
selection.
Results: Preoperative jaundice, age, positive node status, poor differentiation and lymphatic invasion
were significant indicators of poor outcome in multivariate analysis. Absence of jaundice was a highly
favourable prognostic factor. Interaction emerged between jaundice and nodal status. The benefit con-
ferred by the absence of jaundice was restricted to patients in whom negative node status was present.
Five-year overall survival in this group was 66%. Jaundiced patients who underwent preoperative stenting
had a survival advantage.
Conclusions: Preoperative jaundice is a negative risk factor in adenocarcinoma of the pancreas.
Additional studies are required to determine the exact mechanism for this effect.
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Introduction
Adenocarcinoma of the head of the pancreas is an aggressive
cancer with a poor prognosis. In 1886, Nicolas Senn, one of the
fathers of pancreatic surgery, described the association of jaun-
dice with cancer of the head of the pancreas in his book Surgery
of the Pancreas.1 He wrote: ‘It is demonstrated that jaundice is an
invariable symptom of primary scirrhus [referring to cancer] of
the head of the pancreas, while it is uncommon when the disease
affects the body or tail of the organ.’1 Jaundice is still recognized
as one of the most common presenting signs in patients with
ductal adenocarcinoma of the pancreatic head, and occurs in
approximately 75% of this population.2 Jaundice has been shown
to cause immunosuppression in animals and humans.3–6 It also
reduces sinusoidal blood flow within the liver, which is associated
with increased rolling and sticking of leukocytes.7 As a result,
jaundice may promote tumour growth or metastatic implanta-
tion in the liver. The purpose of this study was to determine
whether there is an association between preoperative jaundice
and longterm survival in patients who have undergone resection
of such tumours.
This manuscript was presented at the annual AHPBA meeting, Miami, 7–11
March 2012 and at the 10th World IHPBA Congress, Paris, 1–5 July 2012.
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Materials and methods
Patients and database
All patients who underwent pancreaticoduodenectomy or total
pancreatectomy for adenocarcinoma of the head of the pancreas
during the period from 1 February 1995 to 28 February 2010 were
selected from an institutional pancreaticoduodenectomy data-
base. Since 2007, the database has been prospectively maintained.
For the period prior to 2007, the database was populated from
medical records. The database and studies derived from it are
approved by the institutional review board. The database contains
the variables listed in Table 1. The presence of ‘jaundice’ simply
means that the medical record stated that clinical jaundice was
observed before referral to the surgical service or developed after
referral but prior to surgery. In almost all patients, the former was
true. Results for serum bilirubin were the highest values available.
However, in many cases patients were stented prior to referral and
bilirubin levels at the primary institution were not retrospectively
retrievable. Therefore, the bilirubin levels available were not nec-
essarily the highest recorded at the time a patient presented with
jaundice. The cut-off values for laboratory tests and tumour sizes
were selected prior to analysis and were not altered based on
results.
Operative procedures
A Whipple procedure with antrectomy was the standard proce-
dure performed. Pylorus-sparing pancreatoduodenectomy and
total pancreatectomy were performed occasionally. Frozen sec-
tions of the pancreatic neck and bile duct margins were obtained
routinely in the resected specimen. If the pancreatic neck margin
was positive, additional pancreas was resected until a negative
margin was obtained, or total pancreatectomy was performed.
This was the main indication for total pancreatectomy.
Pathological analysis
Surgical specimens were inked in the operating room in the pres-
ence of a pathologist. Four coloured inks were used for the pan-
creatic neck margin, mesenteric vein margin, uncinate margin and
posterior margin, respectively. When a venous resection was per-
formed, the intimal surface of the vein was not inked (i.e. the
intravascular surface of the vein was not considered to be a
margin). All margins were microscopically evaluated and graded
as R0 (microscopically negative) or R1 (microscopically positive at
margin or tumour within 1 mm of the margin). Specimens were
also evaluated by microscopy for lymphatic, venous and nerve
invasion. Cancers that arose in an intraductal papillary mucinous
neoplasm (IPMN) or a mucinous cystic neoplasm, or which were
described as having mucinous features were not included in the
analysis. This was true whether these pathologies were identified
preoperatively by imaging and in the pathological specimen or in
the pathological specimen only. In the latter, the pathologist
recorded that the tumour had mucinous features or appeared to
arise in an IPMN.
Table 1 Variables tested in 412 patients
Variable Missing, n
Age at surgery, years, mean  SD 65.4  10.4
Gender, male, n (%) 214 (51.9%)
Race,
White, n (%) 371 (90.1%)
Other, n (%) 41 (10.0%)
Weight loss, n (%) 265 (70.3%) Missing 35
Jaundice, n (%) 333 (81.0%) Missing 1
Hypertension, n (%) 218 (53.0%) Missing 1
Diabetes mellitus, n (%) 132 (32.1%) Missing 1
Chronic pancreatitis, n (%) 35 (8.5%) Missing 1
Tobacco use, n (%) Missing 4
Current 106 (26.0%)
Past 157 (35.8%)
Never 156 (38.4%)
Family history of, n (%)
Pancreatic cancer 36 (9.5%) Missing 34
Other gastrointestinal cancer 58 (15.3%) Missing 33
Non-gastrointestinal cancer 186 (48.4%) Missing 28
Haematocrit <25, n (%) 8 (2.0%) Missing 4
Platelet count <250 000/mm3, n (%) Missing 9
Yes 185 (45.9%)
No 218 (54.1%)
AST >100 IU, n (%) 97 (24.6%) Missing 17
Bilirubin >20 mg/dla, n (%) 15 (3.8%) Missing 13
Albumin <3.0 mg/dl, n (%) 34 (8.5%) Missing 10
CA 19-9 >100 IU, n (%) 106 (46.9%) Missing 186
ERCP stent, n (%) 274 (79.0%) Missing 65
Surgery type, n (%) Missing 7
Standard 336 (83.0%)
Pylorus-sparing Whipple 41 (10.1%)
Total pancreatectomy 28 (6.9%)
Vascular resection, n (%) 131 (31.9%) Missing 1
Estimated blood loss 500 ml, n (%) 167 (41.7%) Missing 11
Tumour size, n (%) Missing 17
<2.0 cm 94 (23.8%)
2.0–2.9 cm 147 (37.2%)
3.0–3.9 cm 97 (24.6%)
4 cm 57 (14.4%)
Histological grade, n (%) Missing 7
Good 24 (5.9%)
Moderate 197 (48.6%)
Poor 184 (45.4%)
Lymphatic invasion, n (%) 227 (62.5%) Missing 49
Venous invasion, n (%) 177 (49.3%) Missing 53
Perineural invasion, n (%) 314 (84.0%) Missing 38
Surgical margins, n (%) Missing 3
R0 294 (71.8%)
R1 115 (28.1%)
N-stage, n (%) Missing 4
N0 119 (29.2%)
N1 289 (70.8%)
M-stage, n (%)
M0 408 (98.9%)
M1 4 (1.1%)
aNormal range: 0.1–1.0 mg/dl. Other patients may have had bilirubin levels as high as this
before being stented at outside institutions. Such results, if they occurred, were unavailable.
SD, standard deviation; AST, aspartate transaminase; CA 19-9, carbohydrate antigen 19-9;
ERCP, endoscopic retrograde cholangiopancreatography; N-stage, nodal stage; M-stage,
metastatic stage.
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Survival status
Survival status and date of death, if death had occurred, were
determined from available medical records, institutional or oth-
erwise, and in some patients by searching the Social Security
Death Index (SSDI).
Statistical analysis
The primary outcome was overall survival (OS), which was
defined as the time from surgery to the date of death from any
cause. Survivors were censored at the date of last contact. Distri-
butions of patient and clinical characteristics were compared
between jaundiced and non-jaundiced patients using the chi-
squared test or t-test as appropriate. Survival curves were esti-
mated using the Kaplan–Meier product-limit method. Univariate
Cox proportional hazard models were fit to identify factors sig-
nificantly related to OS. Variables with almost homogeneous
status (i.e. one of two groups comprising <5% of the total sample)
were omitted. For example, with reference to metastasis (M) stage,
the M1 population represented <1% of the total number of
patients and this variable was not entered. To assess whether jaun-
dice was an independent predictor of survival, a multivariate Cox
model was constructed via a backward selection procedure, using
all variables that had attained a P-value of <0.30 in the univariate
analyses. Initially, only those patients for whom complete datasets
were available were included for analysis. Two-way interaction
terms between jaundice and other factors in the multivariate Cox
model were also assessed. As a sensitivity analysis, a multivariate
Cox model was also constructed after the missing values were
imputed using multivariate regression models. All analyses were
two-sided and significance was set at a P-value of 0.05. Statistical
analyses were performed using sasVersion 9.2 (SAS Institute, Inc.,
Cary, NC, USA).
Results
A total of 412 patients underwent resection of a carcinoma of the
head of the pancreas during the study period. The median
number of patients undergoing resection per year was 31 (range:
16–41). Summary statistics are shown in Table 1. An additional
30 patients who demonstrated adenocarcinomas arising in cysts
underwent pancreatoduodenectomy during the period under
study and were excluded from further analysis. The Kaplan–Meier
curve for OS in the 412 patients is shown in Fig. 1. At the time of
analysis, 346 (84%) patients had died and 66 (16%) remained
alive. The median length of survival (follow-up) in patients who
died was 1.18 years (time from surgery to date of death). The
median follow-up of patients who remained alive at the time of
analysis was 4.83 years.
Univariate analysis (Table 2) showed OS to be significantly
related (P < 0.05) to 10 different variables. Three variables includ-
ing jaundice were not significant at the P < 0.05 level, but did
achieve a P-value of <0.30. Therefore, these 13 variables were
included in a backward selection procedure for multivariate
analysis to identify independent predictors of OS. The exclusion of
patients for whom datasets were incomplete (Table 1) left data for
319 (77%) patients available for multivariate analysis.
The results are shown in Table 3. Significant predictors were
jaundice, node status, histological grade, lymphatic invasion and
age. The multivariate analysis showed the interaction between
jaundice and N-stage to be the only significant two-way interac-
tion. The influence of jaundice in N0 patients was found to differ
from that in N1 patients. In N0 patients, those with jaundice had
a much worse prognosis than those without jaundice [hazard ratio
(HR) = 3.01; P = 0.01] (Table 3). However, no significant relation-
ship between the presence or absence of jaundice and survival
emerged in the group of N1 patients. The survival curves for the
four groups of patients categorized according to node status and
the presence or absence of jaundice (N0J0, N1J0, N0J1 and N1J1)
are shown in Fig. 2. Note that 5-year OS in N0J0 patients was 66%
[95% confidence interval (CI) 45–81%] and that this curve dif-
fered significantly from the other three curves. The analysis was
repeated in all 412 patients with imputation of missing values;
similar results were obtained (Table 3).
As jaundice was found to be a risk factor for OS, the effect on
survival of preoperative stenting in jaundiced patients was ana-
lysed. Of the 333 patients who presented with jaundice, informa-
tion regarding preoperative stenting was available in 296 (89%).
Of these, 259 (88%) were stented and 37 (13%) were not. Survival
probability was significantly greater in the stented group (HR =
0.59, 95% CI 0.41–0.85; P = 0.005) (Fig. 3). The difference
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Figure 1 Kaplan–Meier curve for overall survival in the entire set of
patients (n = 412)
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remained significant after adjusting for the other independent risk
factors identified earlier (HR = 0.50, 95% CI 0.33–0.75; P = 0.001).
Discussion
This study examined the relationship between jaundice and sur-
vival in resected patients with adenocarcinoma of the head of the
pancreas. The statistics for age, gender, comorbidities and patho-
logical variables resemble those in prior large case series.8–12 There
are two major findings. Firstly, patients with adenocarcinoma of
the head of the pancreas who presented without clinical jaundice
and who underwent pancreatoduodenectomy had a better prog-
nosis than patients who were jaundiced on presentation. However,
this benefit accrued only to patients who did not have lymph node
Table 2 Univariate analysis of factors affecting overall survival
P-value HRa 95% CI of HR
Variables with a P-value of 0.05 (all included in later multivariate analysis)b
Nodal status N1 versus N0 <0.0001 1.89 1.47–2.46
Lymphatic invasion <0.0001 1.72 1.34–2.20
Histological grade (differentiation)c 0.0002
Moderate versus good 0.032 1.83 1.05–3.18
Poor versus good 0.0008 2.58 1.48–4.49
Venous invasion 0.0096 1.37 1.08–1.73
Age 0.047 1.02 1.01–1.03
Surgical margins 0.010 1.37 1.08–1.75
Tumour sizec 0.0073
2.0–2.9 cm versus <2.0 cm 0.082 1.30 0.97–1.77
3.0–3.9 cm versus <2.0 cm 0.0083 1.55 1.12–2.13
4.0 cm versus <2.0 cm 0.0014 1.83 1.26–2.64
Perineural invasion 0.048 1.39 1.003–1.93
ERCP stent 0.075 0.68 0.51–0.90
Surgery type 0.031
Pylorus-sparing versus standard 0.91 1.02 0.71–1.48
Total pancreatectomy versus standard 0.0091 1.76 1.15–2.68
Variables with a P-value of >0.05 but <0.30 (included in later multivariate analysis)
Jaundice on presentation 0.11 1.28 0.98–1.74
Gender (female) 0.20 0.86 0.70–1.08
Vascular resection 0.23 1.16 0.91–1.46
Variables with a P-value of >0.30a (NOT included in later multivariate analysis)
Diabetes mellitus 0.34
Family history of non-GI cancer 0.36
Hypertension 0.36
Family history of pancreatic cancer 0.42
Weight loss 0.42
Race 0.49
CA 19-9 level 0.58
Estimated blood loss 0.61
Tobacco use 0.83
Aspartate transaminase 0.89
Platelet count 0.96
Family history of other GI cancer 0.97
aHazard ratio and 95% confidence limits given for variables with P < 0.30. A positive value indicates that the variable is associated with a decreased
probability of survival.
bLow haematocrit, bilirubin >20 mg/dl and M status not evaluated by univariate analysis because of low numbers (<5% of total) in one group.
cP-values for the question of whether levels of risk for all groups are equal (type III test).
HR, hazard ratio; 95% CI, 95% confidence interval; ERCP, endoscopic retrograde cholangiopancreatography; GI, gastrointestinal; CA 19-9,
carbohydrate antigen 19-9.
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metastases. Secondly, patients who presented with jaundice and
who were stented prior to surgery had a better prognosis than
patients who were not stented; this advantage seems to be inde-
pendent of other prognostic factors.
There is some evidence in prior studies that preoperative jaun-
dice negatively affects outcomes in patients in whom pancreatic
cancers are resected. Cleary et al. performed a multi-institution
review of 117 patients with pancreatic adenocarcinoma, in 110 of
whom disease was located in the head of the pancreas.9 Preopera-
tive jaundice was identified as a significant negative risk factor on
univariate analysis. However, this did not hold true on multivariate
Table 3 Significant variables in the multivariate analyses
Variables HR (95% CI) P-valuea P-valueb
Jaundice and node status
Non-jaundiced, N0 1
Non-jaundiced, N1 4.92 (2.01–12.05) <0.001 <0.001
Jaundiced, N0 3.01 (1.29–7.01) 0.011 0.012
Jaundiced, N1 4.02 (1.79–9.27) 0.001 <0.001
Age (per 1-year increase) 1.02 (1.01–1.03) 0.004 <0.001
Differentiation
Good 1
Moderate 1.39 (0.78–2.49) 0.262 0.277
Poor 1.93 (1.08–3.47) 0.028 0.017
Lymphatic invasion
No 1
Yes 1.37 (1.05–1.80) 0.023 0.031
aUsing 319 patients without missing values.
bUsing all 412 patients with imputation of missing values.
HR, hazard ratio; 95% CI, 95% confidence interval.
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Figure 2 Kaplan–Meier curves for overall survival in subgroups of
patients categorized according to nodal (N) status and the presence
or absence of jaundice (P < 0.001). N1, lymph node metastasis
present; N0, lymph node metastasis absent; J1, jaundice present;
J0, jaundice absent
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analysis, in which only tumour stage, grade and degree of differ-
entiation were independently associated with survival.9 A study
from the Cleveland Clinic reviewed 179 consecutive pancrea-
toduodenectomies for pancreatic adenocarcinoma.2 This investi-
gation found that an elevated bilirubin level was a significant
negative predictor of OS on univariate analysis. Nevertheless,
upon multivariate analysis serum bilirubin concentration was not
independently prognostic. Instead, elevated liver function tests
[defined in the Cleveland Clinic study2 as elevated alkaline phos-
phatase and/or bilirubin and/or aspartate transaminase (AST)]
were significantly associated with decreased survival. A recent
study of 164 patients from Korea with resected pancreatic adeno-
carcinoma, the majority of whom underwent pancreatoduo-
denectomy, revealed that preoperative bilirubin of <7 mg/dl was
associated with improved survival upon multivariate analysis.13
Jaundice was defined in the current study by the documentation
of clinical jaundice prior to surgery rather than by serum
bilirubin level because of the retrospective nature of the study and
thus the availability of results. Although all patients with a
bilirubin level of >7 mg/dl would be expected to display jaundice,
some of those with levels of <7 mg/dl would also exhibit jaundice
as defined in this study. A 20-year, single-institution experience
with pancreatoduodenectomy for periampullary pathologies at
Indiana University Hospital also investigated the prognostic role
of jaundice.14 Upon multivariate analysis, hyperbilirubinaemia
was predictive of longterm survival in the subset of patients with
periampullary cancer.14 The study did not focus solely on patients
with pancreatic adenocarcinoma, although these patients repre-
sented the majority of those in the periampullary cancer group.
The current study differs from the prior investigations in that an
important relationship between jaundice and nodal status was
identified, whereby the survival benefit to be derived from the
absence of jaundice was observed only in patients who were also
free of nodal metastases. It is possible that the prior studies might
have found a stronger correlation if that relationship had been
known and accounted for.
Two studies have examined the effect on OS of the relief of
jaundice by stenting.15,16 Smith et al. investigated the impact of
jaundice on patients with pancreatic adenocarcinoma undergoing
preoperative biliary stenting, and demonstrated that persistent
jaundice at the time of surgery, despite preoperative biliary drain-
age, was a significant negative predictor of early (6–12 months)
but not overall survival.15 The association between residual jaun-
dice at the time of resection and early survival was independent of
other prognostic factors.15 This study and the present one were not
prospective evaluations of the effect of relief of jaundice on sur-
vival. Both have relatively small groups of patients who were not
stented, so the benefit of stenting on long term survival in this
regard should be considered to be suggestive at this time. Eshuis
et al. performed a randomized controlled trial of early surgery
without relief of jaundice versus preoperative biliary drainage in
patients with periampullary tumors.16 About 60% of their patients
had adenocarcinoma of the pancreas. Total serum bilirubin at
randomization was a negative risk factor for survival in both
univariate and multivariate analyses.16 Median survival was 21.6
months in the stented group and 17.8 months in the early surgery
group, but this difference did not reach statistical significance.16 It
is not possible to directly compare the findings of this previous
study with those of the current study as only a proportion of the
patients in the earlier study had adenocarcinoma of the pancreas.
Although many other studies of perioperative parameters have
compared outcomes in stented and non-stented patients, the
present group were unable to find other studies reporting on
longterm survival.
At least two mechanisms may account for a negative effect of
jaundice on survival. Firstly, tumours that are cicatrizing, and thus
more likely to occlude the bile duct, may be inherently more
aggressive than those that are not. Because cystic tumours may be
less cicatrizing and may have a better prognosis, such tumours
were eliminated from the analysis. The second potential harmful
mechanism refers to the possibility that jaundice has a negative
effect on tumour defences or enables metastasis formation. Jaun-
dice impairs cellular immunity3–6 and reduces liver blood flow,
which is associated with increased rolling and sticking of leuko-
cytes.7 Obviously direct evaluation of the effect of jaundice on
parameters that support tumour growth and implantation in this
patient population is required.
There are several limitations to the current study. Firstly,
patients treated during 2007–2010 were entered into a prospec-
tively maintained database, but data for patients treated prior to
2007 were entered into the database retrospectively by chart
review. Consequently, data on some variables were missing in a
number of patients; these were excluded from the original mul-
tivariate analysis. However, the results did not change when all
patients were studied using imputation of missing results.
Because of the inherently difficult nature of investigating accu-
rate overall disease-specific survival over a 15-year timeframe,
the present authors elected to use OS as the primary endpoint.
As in any study examining OS, outcome may be confounded by
variables such as comorbidities and patient age, which may
influence survival. As overall disease-specific survival was not
evaluated, the relationship of age with OS is probably a reflec-
tion of the fact that older patients are more likely to die of unre-
lated diseases. Finally, it would be desirable to use a quantitative
measure that accounted for both the level and duration of jaun-
dice, but it was not possible to do so in a retrospective study of
this duration.
In conclusion, the absence of jaundice is a highly favourable
predictor of OS in N0 patients with resectable adenocarcinoma in
the head of the pancreas. Recent investigations suggest that jaun-
dice impairs antitumour immunity and promotes metastasis.
Additional study of the factors that favour tumour dissemination
in this patient subset is required.
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